



Pluristem's Dr. Ohad Karnieli to Present at Two Upcoming Scientific Conferences

Presentations to focus on Pluristem's industry-leading expertise in 3D cell culturing and cell expansion technologies

HAIFA, ISRAEL, November 25th, 2014 -- [Pluristem Therapeutics Inc.](#) (NasdaqCM: PSTI; TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today that Dr. Ohad Karnieli, the Company's vice president of development and manufacturing, will present at two scientific conferences on the latest advancements in large-scale cell therapy manufacturing.

On November 25, 2014 at the [11th Annual bioProcessUK Conference](#) Dr. Karnieli will give a presentation titled, "The Road Not Taken-Challenges and Possible Solutions in Moving Cell Therapy from Bench Top to Industry." The bioProcessUK conference will take place in Liverpool, England on November 25-26, 2014 and is organized by the UK BioIndustry Association.

At the [Cell Therapy Manufacturing](#) conference on December 4, 2014 Dr. Karnieli will give a presentation titled, "Challenges and Possible Solutions for Optimizing Cell Therapy Manufacturing and its Influence on Quality and Cost of the Product." He will also be a presenter and panelist for the panel titled, "Top Tips When Moving a Process from Phase I to Phase II to Phase III." The conference will take place from December 3-4, 2014 in Brussels, Belgium, in association with the International Society for Cellular Therapy.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, hematological disorders, radiation damage, and ischemia. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research

institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact:

Pluristem Therapeutics Inc.:

Karine Kleinhaus, MD, MPH
Divisional VP, North America
1-914-512-4109
karinek@pluristem.com